Vancouver-based Clearmind Medicine Inc. has successfully completed the enrollment of six patients for the second cohort in its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary drug candidate aimed at treating Alcohol Use Disorder (AUD). This announcement was made on December 16, 2025, and follows the positive results from the first cohort, which demonstrated a favorable safety profile and initial signs of efficacy, including reduced cravings and withdrawal symptoms.
The second cohort was enrolled rapidly across three prominent clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The swift recruitment process reflects the commitment of these leading institutions to advancing innovative treatments for AUD, a condition that impacts millions globally and currently lacks effective treatment options.
Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine, expressed enthusiasm about the rapid pace of enrollment, stating, “We are thrilled with the accelerated pace of enrollment for our second cohort, which reflects the high level of interest from both patients and leading clinical sites in CMND-100’s potential to transform AUD treatment.” He emphasized that the promising results from the first cohort position the company to gather more valuable data that could lead to a breakthrough therapy addressing the root causes of addiction.
This multinational trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Dosing for the second cohort is expected to begin shortly, with topline results anticipated in the coming months, furthering the company’s objective to develop effective treatments for AUD.
Clearmind Medicine is dedicated to the research and development of novel psychedelic-derived therapeutics aimed at addressing significant health problems. The company’s intellectual property portfolio includes nineteen patent families and 31 granted patents, demonstrating its commitment to innovation in this field. Clearmind intends to pursue additional patents as necessary and remains open to acquiring further intellectual property to enhance its research efforts.
The shares of Clearmind Medicine are publicly traded on Nasdaq under the symbol “CMND” and on the Frankfurt Stock Exchange under “CWY0.” For further information, the company has made its investor relations contact available through the official website.
The completion of this second cohort is a significant step forward for Clearmind Medicine in its quest to revolutionize treatment options for Alcohol Use Disorder. As the clinical trial progresses, the outcomes could pave the way for enhanced therapeutic strategies, offering hope to many seeking effective solutions to addiction-related challenges.